Can antibiotics be used at the same time while taking brigatinib/brigatinib (Embry)?

Brigatinib/Brigatinib (Brigatinib) often encounters a common problem in practical applications: If the patient develops an infection and needs antibiotic treatment, can it be safely used together with the brigatinib regimen? The core of this issue remains related to the metabolic mechanism of brigatinib. Since brigatinib is mainly metabolized by CYP3A, and some antibiotics can also significantly affect the activity of this enzyme, whether it can be used together depends on the type of antibiotic selected.

Some macrolides and certain antifungal drugs have strong CYP3A inhibitory capabilities. When used together with brigatinib, it is easy to increase the concentration of brigatinib and cause dose-related adverse reactions, such as gastrointestinal discomfort, respiratory symptoms, and muscle symptoms. This class of drugs is often considered a combination to be cautious of or avoid. Some broad-spectrum antibiotics, quinolones or β-lactams have little impact on CYP3A, so under strict evaluation, they can be used together with brigatinib, but individual tolerance and symptom changes need to be monitored.

When infectious diseases occur, doctors usually give priority to antibiotics that have less interference with the metabolism of brigatinib and develop the optimal plan based on the severity of the infection, bacterial culture results, and the overall condition of the patient with non-small cell lung cancer. If an antibiotic with a risk of interaction must be used, your doctor may recommend adjusting the brigatinib dose or shortening the duration of antibiotic use to balance the benefits with the risks.

For patients, do not take prescription antibiotics or anti-inflammatory drugs by themselves during brigatinib treatment. Even commonly used anti-infective drugs may cause unpredictable metabolic changes. The addition of any new drugs should be done under the supervision of a doctor, especially during the treatment of infections, and needs to be comprehensively considered in conjunction with liver and kidney function status, drug metabolism capabilities, and potential adverse reactions.

Reference materials:https://www.alunbrig.com/